Filters
A recent study has found the proposed population risk stratification approach using the Steatosis-Associated Fibrosis Estimator (SAFE) score to be simpler and more effective than current guidelines.
In patients with obstructive sleep apnoea (OSA), treatment with sultiame yields improvements in nocturnal hypoxia, sleep quality, and excessive daytime sleepiness, according to a phase II trial.
Patients with autoimmune hepatitis (AIH) do not show an increased risk of overall extrahepatic malignancy compared with controls, but they appear to be at greater risk of lymphoma or myeloma, independent of immunosuppressant use, suggests a study.
The fatty acid synthase inhibitor denifanstat shows potential for treating moderate-to-severe acne vulgaris, with good safety and tolerability, as demonstrated in a study from China presented at EADV 2025.
For older adults with inflammatory bowel disease (IBD), mild endoscopic activity is linked to adverse IBD-specific and morbidity-related outcomes relative to endoscopic remission, as reported in a retrospective study.
New research suggests that engaging in moderate-to-vigorous physical activity can counteract the harmful association between sedentary behaviour and dyslipidaemia by promoting a healthier, more diverse community of gut bacteria.
The melanocortin-4 receptor agonist setmelanotide has demonstrated long-term clinical benefit and an acceptable safety profile in adults with monogenic or syndromic obesity, reports a study.
Treatment with corticosteroid (CTC) plus conventional disease-modifying antirheumatic drug (C-DMARD) demonstrates an acceptable safety profile and appears to be more efficient than CTC alone in patients with nonanterior sarcoidosis-related uveitis, reports a study.
Infection with the human papillomavirus (HPV) appears to increase the risk of developing glaucoma, a recent study has shown.
Administering serial ketamine infusions does not show a clear advantage over serial midazolam infusions for reducing depressive symptoms in patients receiving standard inpatient psychiatric care, according to the KARMA-Dep 2 trial.
